eMedicine Specialties > Ophthalmology > Lid

Blepharospasm, Benign Essential: Follow-up

Author: Robert H Graham, MD, Senior Associate Consultant, Department of Ophthalmology, Mayo Clinic, Scottsdale, Arizona
Contributor Information and Disclosures

Updated: Jun 8, 2009

Follow-up

Further Outpatient Care

  • With treatments, such as BOTOX® injections, the treatment is usually temporary and long-term follow-up care is needed.

Inpatient & Outpatient Medications

Complications

  • Ptosis post BOTOX® injection
  • Palsy after seventh denervation
  • Scarring and edema after myectomy

Prognosis

  • With BOTOX® injections the treatment is usually temporary, and with myectomy the treatment is usually permanent.

Patient Education

  • Inform patient and family of the BEBRF.
  • For excellent patient education resources, visit eMedicine's Procedures Center. Also, see eMedicine's patient education article BOTOX® Injections.

Miscellaneous

Medicolegal Pitfalls

  • Individuals with untreated blepharospasm may be more likely to have work-related or driving accidents.
 
Acknowledgments

The authors and editors of eMedicine gratefully acknowledge the contributions of previous coauthor, Stanley M Saulny, MD, to the development and writing of this article.



More on Blepharospasm, Benign Essential

Overview: Blepharospasm, Benign Essential
Differential Diagnoses & Workup: Blepharospasm, Benign Essential
Treatment & Medication: Blepharospasm, Benign Essential
Follow-up: Blepharospasm, Benign Essential
References
[ CLOSE WINDOW ]

References

  1. Houser M, Waltz T. Meige syndrome and pallidal deep brain stimulation. Mov Disord. Sep 2005;20(9):1203-5. [Medline].

  2. Etgen T, Muhlau M, Gaser C. Bilateral putaminal grey-matter increase in primary blepharospasm. J Neurol Neurosurg Psychiatry. May 11 2006;[Medline].

  3. Fahn S. Blepharospasm: A focal dystonia. In: Bosniak S, ed. Advances in Ophthalmic Plastic and Reconstructive Surgery. Vol 4. Elsevier Science;1985:87-91.

  4. Jankovic J. Etiology and differential diagnosis of blepharospasm and oromandibular dystonia. Adv Neurol. 1988;49:103-16. [Medline].

  5. Jankovic JJ. Clinical features, differential diagnosis, and pathogenesis of blepharospasm and cranial-cervical dystonia. In: Bosniak S, ed. Advances in Ophthalmic Plastic and Reconstructive Surgery. Vol 4. Elsevier Science;1985:67-82.

  6. McCann JD, Gauthier M, Morschbacher R, et al. A novel mechanism for benign essential blepharospasm. Ophthal Plast Reconstr Surg. Nov 1999;15(6):384-9. [Medline].

  7. Horie C, Suzuki Y, Kiyosawa M, Mochizuki M, Wakakura M, Oda K, et al. Decreased dopamine D(2) receptor binding in essential blepharospasm. Acta Neurol Scand. Jun 5 2008;[Medline].

  8. Morrison DA, Mellington FB, Hamada S. Schwartz-Jampel syndrome: surgical management of the myotonia-induced blepharospasm and acquired ptosis after failure with botulinum toxin A injections. Ophthal Plast Reconstr Surg. Jan-Feb 2006;22(1):57-9. [Medline].

  9. Quartarone A, Sant'Angelo A, Battaglia F. Enhanced long-term potentiation-like plasticity of the trigeminal blink reflex circuit in blepharospasm. J Neurosci. Jan 11 2006;26(2):716-21. [Medline].

  10. Hall TA, McGwin G, Searcey K. Health-related quality of life and psychosocial characteristics of patients with benign essential blepharospasm. Arch Ophthalmol. Jan 2006;124(1):116-9. [Medline].

  11. Hall TA, McGwin G, Searcey K. Benign essential blepharospasm: risk factors with reference to hemifacial spasm. J Neuroophthalmol. Dec 2005;25(4):280-5. [Medline].

  12. Munhoz RP, Teive HA, Della Coletta MV. Frequency of obsessive and compulsive symptoms in patients with blepharospasm and hemifacial spasm. Arq Neuropsiquiatr. Jun 2005;63(2A):213-6. [Medline].

  13. Jankovic J, Orman J. Blepharospasm: demographic and clinical survey of 250 patients. Ann Ophthalmol. Apr 1984;16(4):371-6. [Medline].

  14. Bentivoglio AR, Daniele A, Albanese A. Analysis of blink rate in patients with blepharospasm. Mov Disord. Apr 18 2006;[Medline].

  15. Henderson JW. Essential blepharospasm. Trans Am Ophthalmol Soc. 1956;54:453-520.

  16. Malinovsky V. Benign essential blepharospasm. J Am Optom Assoc. Aug 1987;58(8):646-51. [Medline].

  17. Moon NJ, Lee HI, Kim JC. The changes in corneal astigmatism after botulinum toxin-a injection in patients with blepharospasm. J Korean Med Sci. Feb 2006;21(1):131-5. [Medline].

  18. Ronald W. Essential blepharospasm: An often missed diagnosis. In: Bosniak S, ed. Advances in Ophthalmic Plastic and Reconstructive Surgery. Vol 4. Elsevier Science;1985:93-95.

  19. Martino D, Defazio G, Alessio G. Relationship between eye symptoms and blepharospasm: a multicenter case-control study. Mov Disord. Dec 2005;20(12):1564-70. [Medline].

  20. Ben Simon GJ, McCann JD. Benign essential blepharospasm. Int Ophthalmol Clin. 2005;45(3):49-75. [Medline].

  21. Defazio G, Martino D, Aniello MS. A family study on primary blepharospasm. J Neurol Neurosurg Psychiatry. Feb 2006;77(2):252-4. [Medline].

  22. Srivastava T, Goyal V, Singh S. Pallido-pyramidal syndrome with blepharospasm and good response to levodopa. J Neurol. Dec 2005;252(12):1537-8. [Medline].

  23. Weiss EM, Hershey T, Karimi M. Relative risk of spread of symptoms among the focal onset primary dystonias. Mov Disord. May 3 2006;[Medline].

  24. Asanuma K, Carbon-Correll M, Eidelberg D. Neuroimaging in human dystonia. J Med Invest. Nov 2005;52 Suppl:272-9. [Medline].

  25. Dresel C, Haslinger B, Castrop F. Silent event-related fMRI reveals deficient motor and enhanced somatosensory activation in orofacial dystonia. Brain. Jan 2006;129(Pt 1):36-46. [Medline].

  26. Herz NL, Yen MT. Modulation of sensory photophobia in essential blepharospasm with chromatic lenses. Ophthalmology. Dec 2005;112(12):2208-11. [Medline].

  27. Hallett M, Evinger C, Jankovic J, Stacy M. Update on blepharospasm: report from the BEBRF International Workshop. Neurology. Oct 14 2008;71(16):1275-82. [Medline].

  28. Anderson RL, Patel BC, Holds JB, Jordan DR. Blepharospasm: past, present, and future. Ophthal Plast Reconstr Surg. Sep 1998;14(5):305-17. [Medline].

  29. Bradley EA, Bradley D, Bartley GB. Evaluating health-related quality of life in ophthalmic disease: practical considerations. Arch Ophthalmol. Jan 2006;124(1):121-2. [Medline].

  30. Barnes MP, Best D, Kidd L. The use of botulinum toxin type-B in the treatment of patients who have become unresponsive to botulinum toxin type-A -- initial experiences. Eur J Neurol. Dec 2005;12(12):947-55. [Medline].

  31. Bhidayasiri R, Cardoso F, Truong DD. Botulinum toxin in blepharospasm and oromandibular dystonia: comparing different botulinum toxin preparations. Eur J Neurol. Feb 2006;13 Suppl 1:21-9. [Medline].

  32. Cheng CM, Chen JS, Patel RP. Unlabeled uses of botulinum toxins: a review, part 2. Am J Health Syst Pharm. Feb 1 2006;63(3):225-32. [Medline].

  33. Cheng CM, Chen JS, Patel RP. Unlabeled uses of botulinum toxins: a review, part 1. Am J Health Syst Pharm. Jan 15 2006;63(2):145-52. [Medline].

  34. Dutton JJ, White JJ, Richard MJ. Myobloc for the treatment of benign essential blepharospasm in patients refractory to botox. Ophthal Plast Reconstr Surg. May-Jun 2006;22(3):173-7. [Medline].

  35. Seiff SR, Zwick OM. Botulinum toxin management of upper facial rhytidosis and blepharospasm. Otolaryngol Clin North Am. Oct 2005;38(5):887-902. [Medline].

  36. Silveira-Moriyama L, Goncalves LR, Chien HF. Botulinum toxin a in the treatment of blepharospasm: a 10-year experience. Arq Neuropsiquiatr. Jun 2005;63(2A):221-4. [Medline].

  37. Truong D, Comella C, Fernandez HH, Ondo WG. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord. 2008;14(5):407-14. [Medline].

  38. Kenney C, Jankovic J. Botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neural Transm. 2008;115(4):585-91. [Medline].

  39. Roggenkamper P, Jost WH, Bihari K. Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm. Mar 2006;113(3):303-12. [Medline].

  40. Cote TR, Mohan AK, Polder JA. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol. Sep 2005;53(3):407-15. [Medline].

  41. Grandas F, Elston J, Quinn N, Marsden CD. Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatry. Jun 1988;51(6):767-72. [Medline].

  42. Ortisi E, Henderson HW, Bunce C. Blepharospasm and hemifacial spasm: a protocol for titration of botulinum toxin dose to the individual patient and for the management of refractory cases. Eye. Mar 10 2006;[Medline].

  43. Garland PE, Patrinely JR, Anderson RL. Hemifacial spasm. Results of unilateral myectomy. Ophthalmology. Mar 1987;94(3):288-94. [Medline].

  44. Gillum WN, Anderson RL. Blepharospasm surgery. An anatomical approach. Arch Ophthalmol. Jun 1981;99(6):1056-62. [Medline].

  45. Grivet D, Robert PY, Thuret G. Assessment of blepharospasm surgery using an improved disability scale: study of 138 patients. Ophthal Plast Reconstr Surg. May 2005;21(3):230-4. [Medline].

  46. Patel BC. Surgical management of essential blepharospasm. Otolaryngol Clin North Am. Oct 2005;38(5):1075-98. [Medline].

  47. Patil B, Foss AJ. Upper lid orbicularis oculi muscle strip and sequential brow suspension with autologous fascia lata is beneficial for selected patients with essential blepharospasm. Eye. Oct 17 2008;[Medline].

  48. Georgescu D, Vagefi MR, McMullan TF, McCann JD, Anderson RL. Upper eyelid myectomy in blepharospasm with associated apraxia of lid opening. Am J Ophthalmol. Mar 2008;145(3):541-547. [Medline].

  49. Kerty E, Eidal K. Apraxia of eyelid opening: Clinical features and therapy. Eur J Ophthalmol. Mar-Apr 2006;16(2):204-8. [Medline].

  50. Lopez Valdes E, Posada Rodriguez IJ, Bilbao-Calabuig R. Botulinum toxin A injections improve apraxia of eyelid opening without overt blepharospasm associated with neurodegenerative diseases. Mov Disord. Apr 15 2008;23(5):773; author reply 773. [Medline].

  51. Fine PG, Digre KB. A controlled trial of regional sympatholysis in the treatment of photo- oculodynia syndrome. J Neuroophthalmol. Jun 1995;15(2):90-4. [Medline].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

benign essential blepharospasm, BEB, essential blepharospasm

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Robert H Graham, MD, Senior Associate Consultant, Department of Ophthalmology, Mayo Clinic, Scottsdale, Arizona
Robert H Graham, MD is a member of the following medical societies: American Academy of Ophthalmology, American Medical Association, and Arizona Ophthalmological Society
Disclosure: WebMD/eMedicine Salary Employment

Medical Editor

Ron W Pelton, MD, PhD, Private Practice, Colorado Springs, Colorado
Ron W Pelton, MD, PhD is a member of the following medical societies: American Academy of Ophthalmology, American Medical Association, American Society of Ophthalmic Plastic and Reconstructive Surgery, Colorado Medical Society, Utah Medical Association, and Wilderness Medical Society
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

Mark T Duffy, MD, PhD, Consulting Staff, Division of Oculoplastic, Orbito-facial, Lacrimal and Reconstructive Surgery, Green Bay Eye Clinic, BayCare Clinic; Medical Director, Advanced Cosmetic Solutions, A BayCare Clinic
Mark T Duffy, MD, PhD is a member of the following medical societies: American Academy of Ophthalmology, American Medical Association, American Society of Ophthalmic Plastic and Reconstructive Surgery, Sigma Xi, and Society for Neuroscience
Disclosure: Allergan - Botox Cosmetic Consulting fee Consulting; Quest medical - lacrimal balloons Honoraria Speaking and teaching; Ortho-Neutrogenia Consulting fee Consulting

CME Editor

Lance L Brown, OD, MD, Ophthalmologist, Affiliated With Freeman Hospital and St John's Hospital, Regional Eye Center, Joplin, Missouri
Disclosure: Nothing to disclose.

Chief Editor

Hampton Roy Sr, MD, Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences
Hampton Roy Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, and Pan-American Association of Ophthalmology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.